AR079896A1 - Proceso para preparar composiciones farmaceuticas para la liberacion sostenida de analogos de somatostatina - Google Patents
Proceso para preparar composiciones farmaceuticas para la liberacion sostenida de analogos de somatostatinaInfo
- Publication number
- AR079896A1 AR079896A1 ARP110100112A ARP110100112A AR079896A1 AR 079896 A1 AR079896 A1 AR 079896A1 AR P110100112 A ARP110100112 A AR P110100112A AR P110100112 A ARP110100112 A AR P110100112A AR 079896 A1 AR079896 A1 AR 079896A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- weight
- acetic acid
- lanreotide
- pharmaceutical compositions
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 8
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title abstract 2
- 238000013268 sustained release Methods 0.000 title abstract 2
- 239000012730 sustained-release form Substances 0.000 title abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 12
- 239000000203 mixture Substances 0.000 abstract 6
- 108010021336 lanreotide Proteins 0.000 abstract 4
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 abstract 3
- 229960002437 lanreotide Drugs 0.000 abstract 3
- RUGAHXUZHWYHNG-NLGNTGLNSA-N acetic acid;(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5, Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 RUGAHXUZHWYHNG-NLGNTGLNSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000000887 hydrating effect Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 229960001739 lanreotide acetate Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Proceso para preparar composiciones farmacéuticas inyectables para la liberacion sostenida de análogos de somatostatina y composiciones farmacéuticas preparadas de acuerdo con el proceso. En un aspecto preferido, el proceso comprende los pasos de combinar acetato de lanreotido y ácido acético, liofilizar la mezcla resultante una sola vez e hidratar el liofilizado. Puede agregarse ácido acético hasta alcanzar el pH deseado durante el paso final del proceso. Reivindicacion 3: El proceso de la reivindicacion 1, caracterizado porque el ácido es el ácido acético. Reivindicacion 4: El proceso de la reivindicacion 1, caracterizado porque el pH final de la composicion varía entre 5,8 y 6,4. Reivindicacion 7: El proceso de la reivindicacion 1, caracterizado porque en el primer paso se combinan 25 +- 2 g/l de lanreotido y 15 +- 2% en peso de ácido acético. Reivindicacion 12: El proceso de acuerdo con cualquiera de las reivindicaciones 1 a 10, caracterizado porque la cantidad de agua en la que se disuelve el liofilizado es menor que 50%, preferiblemente menor que 30%, más preferiblemente menor que 10% de la cantidad necesaria para disolver completamente la sal de lanreotido, y está adaptada para conferirle a la composicion una consistencia semisolida. Reivindicacion 14: La composicion de la reivindicacion 12, caracterizada porque puede liberar el lanreotido in vivo durante un período de al menos 15 días, preferiblemente de 1 mes, y más preferiblemente de 2 meses. Reivindicacion 15: La composicion de las reivindicaciones 12 o 13, caracterizada porque comprende entre 15 y 35% en peso, preferiblemente 25 +- 5% en peso, y más preferiblemente aproximadamente 24,6 +- 2,5% en peso de lanreotido en forma de base. Reivindicacion 16: La composicion de cualquiera de las reivindicaciones 12 a 14, caracterizada porque es apropiada para usarla después de almacenarla a entre 2 y 8°C durante más de 12 meses, preferiblemente durante más de 24 meses.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29464410P | 2010-01-13 | 2010-01-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079896A1 true AR079896A1 (es) | 2012-02-29 |
Family
ID=43743499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100112A AR079896A1 (es) | 2010-01-13 | 2011-01-13 | Proceso para preparar composiciones farmaceuticas para la liberacion sostenida de analogos de somatostatina |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9352012B2 (es) |
| EP (2) | EP2523653B1 (es) |
| JP (1) | JP6029472B2 (es) |
| KR (1) | KR101915820B1 (es) |
| CN (2) | CN105456206B (es) |
| AR (1) | AR079896A1 (es) |
| AU (1) | AU2011206728B2 (es) |
| BR (1) | BR112012017435A2 (es) |
| CA (1) | CA2786181C (es) |
| DK (1) | DK2523653T3 (es) |
| EA (1) | EA023128B1 (es) |
| ES (1) | ES2677012T3 (es) |
| HU (1) | HUE038200T2 (es) |
| IL (2) | IL220538A (es) |
| MX (1) | MX343112B (es) |
| NZ (1) | NZ600891A (es) |
| PL (1) | PL2523653T3 (es) |
| PT (1) | PT2523653T (es) |
| SG (1) | SG182548A1 (es) |
| TR (1) | TR201809874T4 (es) |
| TW (2) | TW201600108A (es) |
| UA (1) | UA108872C2 (es) |
| WO (1) | WO2011085957A2 (es) |
| ZA (1) | ZA201205160B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6029472B2 (ja) | 2010-01-13 | 2016-11-24 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． | ソマトスタチン類似体（アナログ）の持続的放出のための医薬組成物の製造方法 |
| EP2823808A1 (en) * | 2013-07-09 | 2015-01-14 | Ipsen Pharma S.A.S. | Pharmaceutical composition for a sustained release of lanreotide |
| TW201605488A (zh) | 2013-10-15 | 2016-02-16 | 大塚製藥股份有限公司 | 用以預防及／或治療多囊腎病之藥物 |
| EP3060230A4 (en) | 2013-10-22 | 2017-06-14 | Prolynx LLC | Conjugates of somatostatin and its analogs |
| FR3079421B1 (fr) * | 2018-03-28 | 2024-11-15 | Edix Sa | Presentations injectables, seringues et compositions a liberation prolongee et/ou controlee de lanreotide |
| GR1009814B (el) * | 2019-07-29 | 2020-09-11 | Φαρματεν Α.Β.Ε.Ε. | Φαρμακευτικο σκευασμα που περιλαμβανει ενα πεπτιδιο αναλογο σωματοστατινης |
| RU2742196C1 (ru) * | 2019-09-11 | 2021-02-03 | Общество с ограниченной ответственностью "Медицинские нанотехнологии" | Фармацевтическая композиция для приготовления инъекционного раствора при использовании в лечении магнитной гипертермии и способ ее получения |
| CN112791177B (zh) * | 2019-10-28 | 2023-06-20 | 深圳翰宇药业股份有限公司 | 注射用生长抑素冻干组合物及其制备方法 |
| LU101974B1 (en) | 2020-08-07 | 2022-02-07 | Pharmathen Sa | Process and apparatus for preparing viscous pharmaceutical formulations |
| EP4445950A3 (en) | 2020-08-07 | 2024-12-11 | Pharmathen S.A. | Process and apparatus for preparing viscous pharmaceutical formulations |
| GR1010059B (el) * | 2020-08-10 | 2021-08-13 | Φαρματεν Α.Β.Ε.Ε. | Διαδικασια και συσκευη για την παρασκευη παχυρευστων φαρμακοτεχνικων μορφων |
| WO2023092148A1 (en) * | 2021-11-22 | 2023-05-25 | SpecGx LLC | Injectable sustained release pharmaceutical composition |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH085913B2 (ja) | 1985-09-12 | 1996-01-24 | ザ・アドミニストレ−タ−ズ・オブ・ザ・ツ−レイン・エデユケイシヨナル・フアンド | 治療用ソマトスタチン同族体 |
| PT1288223E (pt) | 1993-08-09 | 2005-03-31 | Sod Conseils Rech Applic | Derivados de peptidos terapeuticos |
| US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| FR2762319A1 (fr) * | 1997-04-18 | 1998-10-23 | Pharma Biotech | Microcapsules presentant une liberation prolongee et leur procede de preparation |
| FR2776520B1 (fr) * | 1998-03-25 | 2000-05-05 | Sod Conseils Rech Applic | Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation |
| TWI294991B (en) * | 1999-09-02 | 2008-03-21 | Fujitsu Ltd | Negative resist composition, method for the formation of resist patterns and process for the production of electronic devices |
| IT1318539B1 (it) | 2000-05-26 | 2003-08-27 | Italfarmaco Spa | Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente |
| US7098305B2 (en) | 2001-09-06 | 2006-08-29 | Ardana Bioscience Limited | Sustained release of microcrystalline peptide suspensions |
| DK1565160T3 (da) | 2002-09-27 | 2014-04-28 | Terna Zentaris Gmbh | Administrationsform til farmaceutisk aktive peptider med vedvarende frigivelse og en fremgangsmåde til fremstilling deraf |
| CN1415378A (zh) * | 2002-10-22 | 2003-05-07 | 南京长澳医药科技有限公司 | 生长抑素冻干粉针及其制备工艺 |
| US6953447B2 (en) | 2002-10-22 | 2005-10-11 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S) | Pre-filled safety injection device with integrated waste collector |
| GB0428151D0 (en) | 2004-12-22 | 2005-01-26 | Novartis Ag | Organic compounds |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| GB0711656D0 (en) | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
| WO2009033741A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of lvv-hemorphin-6 and optionally af12198 as therapeutic agent(s) |
| US20090181068A1 (en) | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
| RU2504360C2 (ru) | 2008-08-12 | 2014-01-20 | Новартис Аг | Фармацевтические композиции |
| EP2168983A1 (fr) | 2008-09-30 | 2010-03-31 | Ipsen Pharma | Nouveaux composés octapeptidiques et leur utilisation thérapeutique |
| US20110250243A1 (en) | 2008-12-15 | 2011-10-13 | Thomas Kissel | Nanoparticle compositions |
| JP6029472B2 (ja) * | 2010-01-13 | 2016-11-24 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． | ソマトスタチン類似体（アナログ）の持続的放出のための医薬組成物の製造方法 |
-
2011
- 2011-01-11 JP JP2012548370A patent/JP6029472B2/ja active Active
- 2011-01-11 HU HUE11701938A patent/HUE038200T2/hu unknown
- 2011-01-11 CN CN201510888218.XA patent/CN105456206B/zh active Active
- 2011-01-11 MX MX2012007802A patent/MX343112B/es active IP Right Grant
- 2011-01-11 CN CN201180005703.8A patent/CN102711728B/zh active Active
- 2011-01-11 CA CA2786181A patent/CA2786181C/en not_active Expired - Fee Related
- 2011-01-11 PT PT117019380T patent/PT2523653T/pt unknown
- 2011-01-11 PL PL11701938T patent/PL2523653T3/pl unknown
- 2011-01-11 BR BR112012017435-5A patent/BR112012017435A2/pt not_active Application Discontinuation
- 2011-01-11 ES ES11701938.0T patent/ES2677012T3/es active Active
- 2011-01-11 EA EA201290637A patent/EA023128B1/ru not_active IP Right Cessation
- 2011-01-11 TW TW104130927A patent/TW201600108A/zh unknown
- 2011-01-11 TW TW100100923A patent/TWI536999B/zh active
- 2011-01-11 EP EP11701938.0A patent/EP2523653B1/en active Active
- 2011-01-11 NZ NZ600891A patent/NZ600891A/en unknown
- 2011-01-11 SG SG2012052403A patent/SG182548A1/en unknown
- 2011-01-11 WO PCT/EP2011/000069 patent/WO2011085957A2/en not_active Ceased
- 2011-01-11 KR KR1020127021004A patent/KR101915820B1/ko active Active
- 2011-01-11 EP EP18165921.0A patent/EP3378468A1/en not_active Withdrawn
- 2011-01-11 US US13/522,297 patent/US9352012B2/en active Active
- 2011-01-11 DK DK11701938.0T patent/DK2523653T3/en active
- 2011-01-11 AU AU2011206728A patent/AU2011206728B2/en active Active
- 2011-01-11 TR TR2018/09874T patent/TR201809874T4/tr unknown
- 2011-01-13 AR ARP110100112A patent/AR079896A1/es not_active Application Discontinuation
- 2011-11-01 UA UAA201209720A patent/UA108872C2/ru unknown
-
2012
- 2012-06-21 IL IL220538A patent/IL220538A/en active IP Right Grant
- 2012-07-11 ZA ZA2012/05160A patent/ZA201205160B/en unknown
-
2016
- 2016-04-27 US US15/139,533 patent/US10206968B2/en active Active
- 2016-10-26 IL IL248510A patent/IL248510A0/en unknown
-
2018
- 2018-12-26 US US16/232,207 patent/US20190167754A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR079896A1 (es) | Proceso para preparar composiciones farmaceuticas para la liberacion sostenida de analogos de somatostatina | |
| ES2656901T3 (es) | Una formulación estabilizada de pemetrexed | |
| ECSP15039103A (es) | Formulación de liberación sostenida de mosapride que proporciona efectos farmacológicos y clínicos con administración una vez al día | |
| PE20130511A1 (es) | Formulaciones de insulina de accion prolongada | |
| PE20200698A1 (es) | Gel que comprende clorhexidina | |
| PE20120204A1 (es) | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas | |
| AR081364A1 (es) | Composiciones farmaceuticas de pazopanib y metodos para su elaboracion | |
| RU2015137145A (ru) | Новые жидкие композиции с повышенной стабильностью | |
| BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
| PE20121405A1 (es) | Excipiente solubilizante para vacunas de virus completo inactivado | |
| AR087857A1 (es) | Composiciones de yodo-povidona estable | |
| CO6270302A2 (es) | Formulaciones solidas de liberacion rapida que incluyen florfenicol y sales farmaceuticamente aceptables del mismo. | |
| JP2015506989A5 (es) | ||
| PE20151205A1 (es) | Formulaciones que contienen linaclotida para administracion oral | |
| HRP20201948T1 (hr) | Pripravci inhibitora dopa-dekarbokilaze | |
| AR077384A1 (es) | Una formulacion farmaceutica inyectable de melfalano. | |
| RU2013133082A (ru) | Композиции тестостерона | |
| AR081870A1 (es) | Composicion farmaceutica que comprende un derivado de amida o sal farmaceuticamente aceptable del mismo | |
| AR082049A1 (es) | Formulaciones liquidas de rupatadina fumarato | |
| PE20140636A1 (es) | Conjugado de naloxol-peg cristalino | |
| AR096854A1 (es) | Composición farmacéutica para una liberación sostenida de lanreotide | |
| PH12015500864A1 (en) | Liquid formulation comprising gm-csf neutralizing compound | |
| PH12013500552A1 (en) | Enhanced transbuccal drug delivery system and compositions | |
| HRP20140676T1 (hr) | Formulacije deoksikolne kiseline i njezinih soli | |
| PE20190707A1 (es) | Formulaciones de buprenorfina de liberacion sostenida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FC | Refusal |